Table 1.
Summary of the results of sofosbuvir in Pakistani patients infected with HCV genotype 3. SVR12/24: Sustained virological response after 12 or 24 weeks of treatment; Hb: hemoglobin; LFT: liver function test; PEG-IFN: pegylated-interferon; RBV: ribavirin; SOF: sofosbuvir; ALP: Alkaline Phosphatase; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase.
| Study | Patient Population/Region (n = Sample Size) | Treatment Regime | SVR 12/24 | Side-Effects/Disadvantage |
|---|---|---|---|---|
| Akhter et al., 2016 [70] | Treatment naïve/Rawalpindi (n = 198) | SOF + RBV | SVR 12 (89.2%) | Fatigue, generalized weakness, headache, and anemia related to ribavirin |
| Siddique et al., 2017 [72] | Treatment naïve and treatment experienced/Karachi (n = 201) | SOF + RBV SOF + RBV + PEG-IFN alfa-2a |
SVR 24 (88.5%) SVR12 (98.5%) |
No side effects reported |
| Sarwar et al., 2017 [71] | Treatment naïve and treatment experienced/Lahore (n = 216) | SOF + RBV SOF + RBV + PEG-IFN alfa-2a |
SVR 24 (82.2%) SVR12 (89.2%) |
Fatigue, headache and fever. Adverse effect was worsening of ascites (4.6% of patients) |
| Azam et al., 2017 [69] | Treatment naïve and treatment experienced/multi-center study (n = 573) | SOF + RBV SOF + RBV + PEG-IFN alfa-2a |
Rapid virological response (RVR) (98.2%) | Fatigue and diarrhea, flu-like symptoms, and other adverse effects |
| Iqbal et al., 2017 [73] | Treatment experienced and treatment naïve/Lahore (n = 1375) | SOF + RBV SOF + RBV + PEG-IFN alfa-2a |
SVR 24 (99.34%) SVR12 (93.46%) |
Headache, fatigue and anemia Less effective in old age, Headache, fatigue and anemia, Myalgia, decreased appetite, hair loss, aggression, depression, leukocytopenia and thrombocytopenia |
| Hanif et al., 2017 [75] | Hemodialysis patients/Karachi (n = 37) | SOF + RBV | SVR24 (100%) | No side effects reported |
| Wahid et al., 2018 [77] | Treatment experienced/Lahore (n = 1, tuberculosis (TB) co-infected patient) | SOF + RBV SOF + daclatasvir |
Non-responder SVR12 |
No side effects reported |
| Saleem et al., 2018 [76] | Treatment naïve/Lahore (n = 5) | SOF + RBV | SVR 24 | Increased LFTs Mild change in ALP, ALT, AST, bilirubin, Hb, and platelets |